CEREVEL (NASDAQ:CERE) INVESTOR ALERT: Cerevel's $45 Per Share Offer is Being Investigated by BFA Law, Shareholders are Encouraged to Contact the Firm

On December 6, 2023, Cerevel Therapeutics announced that it would be acquired by AbbVie. Under the terms of the transaction, AbbVie will acquire all outstanding shares of Cerevel for $45.00 per share in cash. The transaction values Cerevel at a total equity value of approximately $8.7 billion. The boards of directors of both companies have approved the transaction. This transaction is expected to close in the middle of 2024. BFA is currently investigating the go private transaction and believes that Cerevel ...